Neflamapimod inhibits endothelial cell activation, adhesion molecule expression, leukocyte attachment and vascular inflammation by inhibiting p38 MAPKα and NF-κB signaling
Biochemical Pharmacology · 2023
DOI: 10.1016/j.bcp.2023.115683 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2023. Verfasst von Sreelakshmi N Menon und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, Mercer University, Atlanta, GA 30341, USA. Hauptthemen laut MEDLINE: NF-kappa B, Endothelial Cells. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 59 Literaturangaben.
Abstract (Originalsprache)
Neflamapimod, a selective inhibitor of the alpha isoform of p38 mitogen-activated protein kinase (MAPKα), was investigated for its potential to inhibit lipopolysaccharide (LPS)-induced activation of endothelial cells (ECs), adhesion molecule induction, and subsequent leukocyte attachment to EC monolayers. These events are known to contribute to vascular inflammation and cardiovascular dysfunction. Our results demonstrate that LPS treatment of cultured ECs and rats leads to significant upregulation of adhesion molecules, both in vitro and in vivo, which can be effectively inhibited by neflamapimod treatment. Western blotting data further reveals that neflamapimod inhibits LPS-induced phosphorylation of p38 MAPKα and the activation of NF-κB signaling in ECs. Additionally, leukocyte adhesion assays demonstrate a substantial reduction in leukocyte attachment to cultured ECs and the aorta lumen of rats treated with neflamapimod. Consistent with vascular inflammation, LPS-treated rat arteries exhibit significantly diminished vasodilation response to acetylcholine, however, arteries from rats treated with neflamapimod maintain their vasodilation capacity, demonstrating its ability to limit LPS-induced vascular inflammation. Overall, our data demonstrate that neflamapimod effectively inhibits endothelium activation, adhesion molecule expression, and leukocyte attachment, thereby reducing vascular inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, College of Pharmacy, Mercer University, Atlanta, GA 30341, USA.
- Department of Pharmaceutical Sciences, College of Pharmacy, Mercer University, Atlanta, GA 30341, USA; Department of Biological Sciences, Augusta University, Augusta, GA, USA.
- Tenaya Therapeutics, South San Francisco, CA, USA.
- Department of Pharmaceutical Sciences, College of Pharmacy, Mercer University, Atlanta, GA 30341, USA; Department of Biomedical Sciences, School of Medicine, Mercer University, Macon, GA, USA.
- Department of Pharmaceutical Sciences, College of Pharmacy, Mercer University, Atlanta, GA 30341, USA. Electronic address: hasan_r@mercer.edu.
Zitieren
APA
Menon, S. N., Zerin, F., Ezewudo, E., Simon, N. P., Menon, S. N., Daniel, M. L., Green, A. J., Pandey, A., Mackay, C. E., Hafez, S., Moniri, N. H., & Hasan, R. (2023). Neflamapimod inhibits endothelial cell activation, adhesion molecule expression, leukocyte attachment and vascular inflammation by inhibiting p38 MAPKα and NF-κB signaling. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2023.115683
Vancouver
Menon SN, Zerin F, Ezewudo E, Simon NP, Menon SN, Daniel ML, et al. Neflamapimod inhibits endothelial cell activation, adhesion molecule expression, leukocyte attachment and vascular inflammation by inhibiting p38 MAPKα and NF-κB signaling. Biochemical Pharmacology. 2023. doi:10.1016/j.bcp.2023.115683
BibTeX
@article{Menon2023,
author = {Menon, Sreelakshmi N and Zerin, Farzana and Ezewudo, Emmanuella and Simon, Nimi P and Menon, Sreeranjini N and Daniel, Morgan L and Green, Andrea J and Pandey, Ajay and Mackay, Charles E and Hafez, Sherif and Moniri, Nader H and Hasan, Raquibul},
title = {Neflamapimod inhibits endothelial cell activation, adhesion molecule expression, leukocyte attachment and vascular inflammation by inhibiting p38 MAPKα and NF-κB signaling},
journal = {Biochemical Pharmacology},
year = {2023},
doi = {10.1016/j.bcp.2023.115683}
}
EUVIMED